Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
06 May 2020 | Story Nitha Ramnath


The quality of the following University of the Free State (UFS) Accountancy programmes is internationally recognised, as it has been accredited by the Association of Chartered Certified Accountants (ACCA) after a thorough review of the modules offered:

• Bachelor of Accountancy (BAcc)
• Bachelor of Commerce Honours in Accounting (BComHons in Accounting)
• Postgraduate Diploma in General Accounting (PGDip [General Accountancy])

The implications of this accreditation are that graduates of these programmes will be eligible for direct admission to the Strategic Professional level (i.e. the highest level) of the ACCA qualification structure – a level aimed at preparing students for future leadership positions. Graduates of the BCom Accounting (BCom [Accounting]) programme will receive exemption from all of the ACCA’s ‘applied knowledge’ examinations as well as many of its ‘applied skills’ examinations.

According to the ACCA website: “We’re a thriving global community of 219 000 members and 527 000 students based in 179 countries that upholds the highest professional and ethical values.” 

Internationally recognised accreditation

Haneke van Zyl, the Programme Director: General Accountancy and Research at the UFS, commented: “As this designation is internationally recognised, the ACCA accreditation of our programmes is vital in the School of Accountancy’s quest to acknowledge our diverse student body and to provide a wide range of opportunities to our Accounting students.  We believe that each of our students should be empowered to become the best versions of themselves – and this accreditation will open more doors for them.”  

As a result of this accreditation, ACCA will also actively assist UFS graduates of the aforementioned programmes to pursue ACCA membership through programmes such as ‘Accelerate’, which subsidises the various fees payable by aspirant members of ACCA.

Prof Frans Prinsloo, the Director of the School of Accountancy at the UFS, added: “We are very proud of the quality of our programmes – which are now accredited by all the leading professional bodies that operate in South Africa, i.e. the SA Institute of Chartered Accountants (SAICA), the SA Institute of Professional Accountants (SAIPA), the Chartered Institute of Management Accountants (CIMA) and most recently, the Association of Chartered Certified Accountants (ACCA).  This is testament not only to the quality of the school’s curricula and teaching and learning resources, but vitally important also to the calibre of academic staff – who are not only highly qualified and experienced in facilitating teaching and learning, but also committed to their students’ success.” 
 
Van Zyl added: “We have drawn on the curriculum structures of these leading professional bodies to inform our curricula – thereby ensuring the continued relevance of our graduates in the fast changing world of work that is being transformed by the 4th Industrial Revolution. Far from becoming obsolete in this environment, appropriately qualified accountants will become key providers of credible information for organisational decision-making – a function without which no organisation can be successful and thrive.” 

Prof Prinsloo acknowledged the hard work of the colleagues in developing all the required documents needed to obtain the ACCA accreditation: “The accreditation is the result of a combined effort by the colleagues from the School of Accountancy, guided by the responsible programme director, Mrs Haneke van Zyl. It is testament to the hard work and effort that the lecturers involved in the programmes have put in.”


News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept